References
- Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):1–21.
- Schneider BJ, Daly ME, Kennedy EB, et al. Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline Summary. J Oncol Pract. 2018;14(3):180–186.
- Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–1076.
- Nyman J, Hallqvist A, Lund JÅ, et al. SPACE – a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol. 2016;121(1):1–8.
- Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010;28(35):5153–5159.
- Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):348–353.
- Nagata Y, Hiraoka M, Shibata T, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93(5):989–996.
- Subramanian MP, Meyers BF. Surgical resection versus stereotactic body radiation therapy for stage I NSCLC: can randomized trials provide the solution? Cancers (Basel). 2018;10(9):310.
- Zhang B, Zhu F, Ma X, et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;112(2):250–255.
- Wouters MW, Jansen-Landheer ML, van de Velde CJ. The quality of cancer care initiative in the Netherlands. Eur J Surg Oncol. 2010;36(1):3–13.
- Damhuis RA, Maat AP, Plaisier PW. Performance indicators for lung cancer surgery in the Netherlands. Eur J Cardiothorac Surg. 2015;47(5):897–903. 903–904.
- Ten Berge M, Beck N, Heineman DJ, et al. Dutch Lung Surgery Audit: a national audit comprising lung and thoracic surgery patients. Ann Thorac Surg. 2018;106(2):390–397.
- Von Meyenfeldt EM, Gooiker GA, van Gijn W, et al. The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. J Thorac Oncol. 2012;7(7):1170–1178.
- Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15(1):4–9.
- Rankin NM, McGregor D, Stone E, et al. Evidence-practice gaps in lung cancer: a scoping review. Eur J Cancer Care (Engl). 2018;27(2):e12588.
- Heineman DJ, Ten Berge MG, Daniels JM, et al. Clinical staging of stage I non-small cell lung cancer in the Netherlands – need for improvement in an era with expanding nonsurgical treatment options: data from the Dutch Lung Surgery Audit. Ann Thorac Surg. 2016;102(5):1615–1621.
- Owen D, Chaft JE. Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis. 2018;10(3):404–411.